Clinical Trial: MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Sch

Brief Summary: The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Mean change from baseline at 4 weeks of treatment on a sequence of cognitive tests and that MK0557 generally well tolerated [ Time Frame: at 4 weeks of treatment ]

Original Primary Outcome:

Current Secondary Outcome: Mean change from baseline at 4 weeks of treatment on neuropsychological tests for executive functioning, episodic memory and working memory [ Time Frame: at 4 weeks of treatment ]

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: May 31, 2007
Date Started: September 2007
Date Completion:
Last Updated: August 20, 2015
Last Verified: August 2015